|14.53||+0.1300||+0.90%||Vol 1.10M||1Y Perf 121.54%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||0.29 2.00%|
|Target Price||24.63||Analyst Rating||Strong Buy 1.10|
|Potential %||69.51||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-100/-50||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-100/-84||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-70||Income Ranking||— -|
|Price Range Ratio 52W %||52.52||Earnings Rating||—|
|Market Cap||1.10B||Earnings Date||9th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th Nov 2023|
|Estimated EPS Next Report||-0.50|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.31M|
|Avg. Monthly Volume||1.12M|
|Avg. Quarterly Volume||923.10K|
89bio Inc. (NASDAQ: ETNB) stock closed at 14.53 per share at the end of the most recent trading day (a 0.9% change compared to the prior day closing price) with a volume of 1.10M shares and market capitalization of 1.10B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. 89bio Inc. CEO is Rohan Palekar.
The one-year performance of 89bio Inc. stock is 121.54%, while year-to-date (YTD) performance is 14.14%. ETNB stock has a five-year performance of %. Its 52-week range is between 5.24 and 22.93, which gives ETNB stock a 52-week price range ratio of 52.52%
89bio Inc. currently has a PE ratio of -2.60, a price-to-book (PB) ratio of 3.52, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -56.27%, a ROC of -63.31% and a ROE of -69.29%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from 89bio Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. 89bio Inc.’s next earnings report date is 09th Nov 2023.
The consensus rating of Wall Street analysts for 89bio Inc. is Strong Buy (1.1), with a target price of $24.63, which is +69.51% compared to the current price. The earnings rating for 89bio Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
89bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
89bio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.51, ATR14 : 0.94, CCI20 : -141.94, Chaikin Money Flow : -0.03, MACD : -0.55, Money Flow Index : 20.11, ROC : -17.05, RSI : 35.38, STOCH (14,3) : 12.12, STOCH RSI : 0.00, UO : 42.98, Williams %R : -87.88), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of 89bio Inc. in the last 12-months were: Atkinson Edward Morrow III (Option Exercise at a value of $16 312), Atkinson Edward Morrow III (Sold 6 250 shares of value $111 938 ), Edward Morrow Atkinson (Option Excercise at a value of $44 400), Edward Morrow Atkinson (Sold 10 000 shares of value $136 000 ), Edward Morrow Iii Atkinson (Option Excercise at a value of $60 713), Hayden Michael (Buy at a value of $993 839), Le-Nguyen Quoc (Sold 0 shares of value $-247 466 ), Le-Nguyen Quoc (Sold 13 683 shares of value $247 799 ), Martins Ryan (Sold 0 shares of value $-9 330 ), Martins Ryan (Sold 27 280 shares of value $388 782 ), Michael Hayden (Buy at a value of $993 839), Palekar Rohan (Sold 0 shares of value $-28 950 ), Palekar Rohan (Sold 30 000 shares of value $540 000 ), Rohan Palekar (Sold 15 000 shares of value $240 000 ), Ryan Martins (Option Excercise at a value of $9 330), Ryan Martins (Sold 27 280 shares of value $388 782 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.